# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Chardan Capital analyst Keay Nakae maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and maintains $31 price target.
Oppenheimer analyst Francois Brisebois reiterates Dyne Therapeutics (NASDAQ:DYN) with a Outperform and maintains $47 price t...
HC Wainwright & Co. analyst Andrew Fein reiterates Dyne Therapeutics (NASDAQ:DYN) with a Buy and maintains $36 price tar...
Morgan Stanley analyst Michael Ulz initiates coverage on Dyne Therapeutics (NASDAQ:DYN) with a Overweight rating and announc...
Oppenheimer analyst Francois Brisebois reiterates Dyne Therapeutics (NASDAQ:DYN) with a Outperform and maintains $47 price t...
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday.
Cantor Fitzgerald initiates coverage on Avidity Biosciences highlighting a robust pipeline led by del-desiran, a promising trea...